US Bancorp DE Sells 13,404 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

US Bancorp DE trimmed its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 58.2% in the 3rd quarter, Holdings Channel reports. The fund owned 9,632 shares of the company’s stock after selling 13,404 shares during the quarter. US Bancorp DE’s holdings in Teva Pharmaceutical Industries were worth $174,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Oppenheimer & Co. Inc. boosted its holdings in Teva Pharmaceutical Industries by 9.6% in the 1st quarter. Oppenheimer & Co. Inc. now owns 13,522 shares of the company’s stock valued at $191,000 after purchasing an additional 1,180 shares during the period. Sei Investments Co. grew its position in Teva Pharmaceutical Industries by 0.9% during the first quarter. Sei Investments Co. now owns 457,322 shares of the company’s stock worth $6,453,000 after buying an additional 4,000 shares in the last quarter. State Board of Administration of Florida Retirement System increased its stake in Teva Pharmaceutical Industries by 13.4% during the first quarter. State Board of Administration of Florida Retirement System now owns 62,018 shares of the company’s stock valued at $875,000 after acquiring an additional 7,335 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in Teva Pharmaceutical Industries by 36.3% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 627,691 shares of the company’s stock valued at $8,857,000 after acquiring an additional 167,097 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Teva Pharmaceutical Industries by 3.5% in the 1st quarter. Vanguard Group Inc. now owns 825,537 shares of the company’s stock worth $11,648,000 after acquiring an additional 28,071 shares during the period. 54.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on TEVA. JPMorgan Chase & Co. upped their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. UBS Group lifted their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $19.67.

Teva Pharmaceutical Industries Stock Down 1.1 %

TEVA opened at $16.75 on Friday. Teva Pharmaceutical Industries Limited has a twelve month low of $8.64 and a twelve month high of $19.31. The firm has a market cap of $18.98 billion, a price-to-earnings ratio of -19.71, a PEG ratio of 1.34 and a beta of 0.87. The firm’s 50-day simple moving average is $17.84 and its 200-day simple moving average is $17.20. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.